ArticleBMJ (Clinical research ed.)2018
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).
Abstract read
In one paragraph
Article in BMJ (Clinical research ed.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 342 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
342citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
342 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Estimating the Prevalence of Prescribed Medication Use in Pregnancy with a Systematic Review and Meta-analysis.Drug safety · 2026Pooled it
- Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.Headache · 2026Pooled it
- Identifying, handling and impact of immortal time bias on addressing treatment effects in observational studies using routinely collected data.BMC medical research methodology · 2025Pooled it
- Association Between β-Adrenoreceptor Agonists and Antagonists and Parkinson's Disease: Systematic Review and Meta-Analysis.Pharmacoepidemiology and drug safety · 2025Pooled it
- Patient and Public Involvement in Pharmacoepidemiological Research: An Environmental Scan of an Emerging Area.Pharmacoepidemiology and drug safety · 2025Pooled it
- Drug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION.Journal of pregnancy · 2024Pooled it
- Quantifying Potential Immortal Time Bias in Observational Studies in Acute Severe Infection.Open forum infectious diseases · 2025Trial
- Association of hypertension and diabetes with opioid initiation and progression to long-term use after osteoarthritis diagnosis: A population-based register cohort study in Sweden.Osteoarthritis and cartilage open · 2026Article
- Article
- Initiation of SGLT2 Inhibitors Versus DPP-4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims-Based Active-Comparator New-User Study.Diabetes, obesity & metabolism · 2026Article
- Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.Diabetes, obesity & metabolism · 2026Article
- Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2026Article
- Healthcare Cost Impacts of Telehealth-Delivered Nutrition Therapy among US Adults with Type 2 Diabetes or Obesity: A Matched Difference-in-Differences Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Long-Term Proton Pump Inhibitor Therapy Is Common Among Older Adults: An 8-Year Finnish Nationwide Register Study.Drugs & aging · 2026Article
- Reproducibility in biomedical research.Nature medicine · 2026Review
- Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis.International journal of clinical pharmacy · 2026Article
- Interpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluation.Drug safety · 2026Review
- Statin Continuation After an Index Hospitalization for Hepatic Decompensation in MASLD Cirrhosis.Digestive diseases and sciences · 2026Article
- Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review.ESMO real world data and digital oncology · 2026Review
- Supratherapeutic drug concentration triggers: A novel data-driven approach to assess their value for medication safety surveillance in intensive care.British journal of clinical pharmacology · 2026Article
282 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Sinéad M LanganFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK sinead.langan@lshtm.ac.uk.
Sigrún Aj SchmidtDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Kevin WingFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Vera EhrensteinDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Stuart G NichollsOttawa Hospital Research Institute, Ottawa, ON, Canada.
Kristian B FilionDepartments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
Olaf KlungelDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Irene PetersenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Henrik T SorensenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
William G DixonArthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Astrid GuttmannInstitute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Katie HarronICH Population, Policy, and Practice Programme, University College London, Great Ormond Street Institute of Child Health, London, UK.
Lars G HemkensBasel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
David MoherOttawa Hospital Research Institute, Ottawa, ON, Canada.
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Liam SmeethFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Miriam SturkenboomJulius Global Health, University Medical Center Utrecht, Utrecht, Netherlands.
Erik von ElmCochrane Switzerland, Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland.
Shirley V WangDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Eric I BenchimolInstitute for Clinical Evaluative Sciences, Toronto, ON, Canada.
Funding
Department of Health NIHR/CS/010/014Medical Research Council G0902272Medical Research Council MC_PC_13042Medical Research Council MR/K006665/1Wellcome Trust 205039/Z/16/Z
Abstract
PubMed holds no abstract for this paper.
Indexed as
Data CollectionGuidelines as TopicObservational Studies as TopicHumansPharmacoepidemiologyResearch Report
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.